Print this page
-
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability,
Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination
Therapy in Participants with KRAS-Altered Advanced or Metastatic Solid Tumors
Protocol: 052506Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Tumors.
Protocol: 052509Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Esophagus
Lung
Other Digestive Organ
Pancreas
Thyroid -
A Phase 1/Randomized Phase 2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma.
Protocol: 072403Principal Investigator:
- Matthew Deek
Applicable Disease Sites: Pancreas -
Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Metastatic Castration-Resistant Prostate Cancer.
Protocol: 082105Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma.
Protocol: 082409Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
A Phase I Study to Evaluate the Safety of Naltrexone and Propranolol in Combination with Standard of Care Ipilimumab and Nivolumab in Patients with Advanced Melanoma.
Protocol: 092302Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO).
Protocol: 092305Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status.
Protocol: 102302Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Other Female Genital -
A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers.
Protocol: 102402Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Ovary -
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers.
Protocol: 102405Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Corpus Uteri
Ovary -
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors.
Protocol: 112401-01APrincipal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site -
LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
Protocol: 112401-01CPrincipal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site -
Mindfulness-based ecological momentary intervention for smoking cessation among cancer survivors
Protocol: 132413Applicable Disease Sites:
-
A Pilot Prospective Trial to Assess the Feasibility of Preoperative Partial Breast Radiation in Breast Cancer Patients.
Protocol: 152502Principal Investigator:
- Nisha Ohri
Applicable Disease Sites: Breast -
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the Stomach, Breast, Lung and Cervix.
Protocol: 192004Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Any Site
Breast
Cervix
Lung
Stomach -
A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers.
Protocol: 192104Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Breast
Cervix
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital
Stomach